Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback